🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Submit your abstracts!

Now online Clinical Cancer Research : Preop SAbR in #PancreaticCancer is associated with locoregional control—especially with arterial involvement—and reveals immune activation. Peter Leung was outstanding leading this to pub! #RadOnc UTSW Simmons Cancer Center @UTSWNews bit.ly/457oz6b

Join us at PTCOG 63 to explore cutting-edge particle therapy and novel Phase III randomized studies comparing IMRT and IMPT. With advancements in LET optimization, immune modulation, we are moving PT into the new era.

#UTSW broke ground on a new 65,000-square-foot Radiation Oncology campus in Fort Worth. The facility will feature the city’s first MRI-guided precision radiation treatment and will enhance access to advanced cancer treatments. Read more. bit.ly/439JOSn UTSW Radiation Oncology

Would argue that lymphomas are one of the most important diseases to consider adaptive RT as they are exquisitely radiosensitive, often in difficult to target locations, and many have long term survival so even small decreases in dose to OARs are likely meaningful. Excited… 1/2

This report highlights the incredible work our Radiation Therapists, Physicists, and Physicians put in to build a highly recognized and one-of-a-kind adaptive radiotherapy program. Their collective impact on this developing treatment paradigm is impressive to sit back and observe

❗️ CM577 CRT -> surgery -> non-pCR randomized to adjuvant nivolumab vs placebo Primary endpoint: DFS First OS results: mOS 51.7 vs 35.3 mo HR 0.85 (95.87% CI 0.70–1.04)

Sharing our latest article out in Cureus "Survival Disparities in Adenocarcinoma Within Adenomatous Polyps: A National Cancer Database Analysis" cureus.com/articles/36291… A small project that offered Deepak Vadehra and I the opportunity to mentor some Creighton University med students

#ASCO2025 🚨 BREAKWATER OS data lands—and it must redefine 1L standard of care in BRAF V600E-mutant mCRC. EC + mFOLFOX6 vs SOC (chemo ± bevacizumab): 📊 PFS: 12.8 vs 7.1 mo (HR 0.53, p < 0.0001) 🧬 OS: 30.3 vs 15.1 mo (HR 0.49, p < 0.0001) ✅ Dual primary endpoints met 🛡️

Come on #ASCO25, this 💯 should have been a plenary! 7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater than benefit for adding oxali to 5-FU (5% at 10 yrs in MOSAIC). Exercise = $ effective, ~0 tox, & gives pts sense of empowerment. Congrats Chris Booth et al!

Submit your abstracts! It's going to be an amazing meeting!

Nina Niu Sanford Highlighted Role of NCI National Clinical Trials Network in Cancer Research Dr. Nina Niu Sanford Ted Hong Thomas George, MD, FACP, FASCO oncodaily.com/insight/nci-na… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews CancerWorld

Join us for PTCOG-NA in Louisiana! Abstract deadline tomorrow!

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, NRG Oncology for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏

Great work by Neil Desai and UTSW Radiation Oncology!

Can't wait for this meeting!

Please consider enrolling & feel free to reach out to our study team w any questions. Happy Friday!

Celebrate our new award winners who are accelerating RT for non-cancerous conditions Carmen Bergom MD PhD WashU Medicine Radiation Oncology Khashayar Fattah, MD Robert Timmerman UTSW Radiation Oncology Michelle Iocolano John Plastaras Penn Radiation Oncology Residency Sue Yom UCSFRadiationOncology More on their pioneering research bit.ly/ROI2025Innovat…

❗️ STELLAR-303 zanzalintinib + atezolizumab vs regorafenib in MSS CRC is “positive” for OS More specific data here is pending publication; can we add to CRT for MSS rectal cancer to improve organ preservation? Dr. Nina Niu Sanford Krishan Jethwa ir.exelixis.com/news-releases/…

A modality where you can objectively treat 100 percent of the tumor should not be omitted especially in the modern era Not to mention TACE yields multiple retreatments , and terrible post tace syndrome of sickness and nausea … and financial as well as time toxicity to patients